EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study

Izaya Nakaya, Ken-Ei Sada iD, Masayoshi Harigai iD, Jun Soma, Koichi Amano, Hiroaki Dobashi, Tatsuya Atsumi, Yukio Yuzawa, Shouichi Fujimoto, Takahiko Sugihara, Yoshinari Takasaki, Yoshihiro Arimura und 1 weitere

Modern Rheumatology · 01.11.2023 · 33 (6) · 1137-1144

DOI: 10.1093/mr/roac124 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, online erschienen am 05.10.2022. Verfasst von Izaya Nakaya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Pneumocystis carinii. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Ministry of Health, Labour, and Welfare, Japan, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study investigated the current practice of prophylactic treatment against Pneumocystis jirovecii pneumonia (PCP) and its effectiveness in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Methods

This study included 319 patients registered from 53 institutions in Japan and newly diagnosed with AAV. During the 2-year observation period, we examined the frequency of usage, effectiveness and safety of prophylactic drugs against PCP.

Results

Most patients received prophylactic drugs against PCP with the initiation of immunosuppressive agents, and >50% of them remained on chemoprophylaxis against PCP at 2 years after. The initial daily dose of oral prednisolone and the proportion of cyclophosphamide administration were higher in patients who received chemoprophylaxis against PCP than in those who did not. PCP occurred in nine patients (3%) and resulted in the death of four. The incidence rate of PCP in patients who received chemoprophylaxis was 1.13/100 patient-years (95% confidence interval, 0.38–2.68) and that in those who did not was 2.74 (1.04–6.02). The incidence rate ratio was 0.41 (0.11–1.53).

Conclusions

The markedly low incidence of PCP may be attributed to the continuous chemoprophylaxis against PCP received by >50% of Japanese patients with AAV, although the effectiveness of chemoprophylaxis against PCP was not statistically confirmed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPneumocystis cariniiHumansEast Asian PeopleImmunosuppressive AgentsChemoprevention

Stichwörter der Autor:innen

Anti-neutrophil cytoplasm antibodygranulomatosis with polyangiitisinfectionmicroscopic polyangiitissystemic vasculitis

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan.
  • Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.
  • Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Department of Rheumatology and Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan.
  • Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Japan.

ORCID-Profile: Ken-Ei Sada, Masayoshi Harigai

Förderung

  • Ministry of Health, Labour, and Welfare, Japan
  • Japan Agency for Medical Research and Development

Zitieren

APA

Nakaya, I., Sada, K. E., Harigai, M., Soma, J., Amano, K., Dobashi, H., Atsumi, T., Yuzawa, Y., Fujimoto, S., Sugihara, T., Takasaki, Y., Arimura, Y., & Makino, H. (2023). Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study. Modern Rheumatology, 33(6), 1137-1144. https://doi.org/10.1093/mr/roac124

Vancouver

Nakaya I, Sada KE, Harigai M, Soma J, Amano K, Dobashi H, et al. Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study. Modern Rheumatology. 2023;33(6):1137-1144. doi:10.1093/mr/roac124

BibTeX
@article{Nakaya2023,
  author = {Nakaya, Izaya and Sada, Ken-Ei and Harigai, Masayoshi and Soma, Jun and Amano, Koichi and Dobashi, Hiroaki and Atsumi, Tatsuya and Yuzawa, Yukio and Fujimoto, Shouichi and Sugihara, Takahiko and Takasaki, Yoshinari and Arimura, Yoshihiro and Makino, Hirofumi},
  title = {Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study},
  journal = {Modern Rheumatology},
  year = {2023},
  volume = {33},
  number = {6},
  pages = {1137--1144},
  doi = {10.1093/mr/roac124}
}
Kostenlos starten →